

Challenges and Opportunities for Developing Countries Regarding Life-sciences Innovation

Stephen Ezell
VP, Global Innovation Policy
ITIF

Global Trade and Innovation Policy Alliance Annual Summit


Mexico City, Mexico
June 13, 2019

Innovate4Health Initiative

Innovate4Health

Innovate4Health

How Innovators Are Solving Global Health Challenges
Editors: Mark Schultz, Stephen Ezell, and David Lund



Featuring Original Case Studies Authored By:

Jaci Arthur
Nick Churchill
Nigel Cory
Gabrielle Eriquez
Stephen Ezell
Maryna Koberidze
Andrew B. Levey

David Lund
Kevin Madigan
Michael O'Keefe
Gleb Savich
Alex Summerton
Bhamati Viswanathan



Innovate4Health
AMÉRICA LATINA

How Innovators Are Solving Global Health Challenges




Featuring Original Case Studies Authored By:

Jaci Arthur,
Stephen Ezell,
Mark Schultz,
and Philip Stevens



Innovate4Health: IP-driven Innovation In Healthcare Is Happening **Everywhere**



Lessons Learned From the I4H Case Studies

- Developing countries have unique challenges, but global health challenges are increasingly commonly shared.
 - 70% of fatalities in developing world from non-communicable diseases.
- However, access challenges remain significant.
 - More than two billion individuals lack adequate access to essential medical products/supplies.
- Innovative medicines are part of the solution, not the problem.

Mexico's Robust Life-Sciences Sector

Mexican pharmaceutical industry

Mexico has the 2nd largest biopharmaceutical market in Latin America and the 11th largest in the world.

Proportion of GDP	1.2%	Growth of 0.7% from 2007
Proportion of Manufacturing GDP	6.8%	Significant manufacturing sector in Mexico
Direct Jobs	86,277	37% linked to manufacturing
Indirect Jobs	313, 605	Includes jobs in other companies from which the pharmaceutical industry buys goods or services
Sector growth	4.3%	Between 2007 and 2013
Economic units	718	Companies located mainly in Mexico City, Jalisco, Estado de México and Puebla.
Multinational biopharmaceutical industry	20 of 25	Top multinational biopharmaceutical companies operate in Mexico
Investment in R&D	US\$500m by 2025	Increase of US\$160m from 2015
Biotechnology drugs	65% by 2030	Proportion of patent applications for new medicines

Sources: Mexican Health Review 2015, Marketline, INEGI, COFEPRIS, Denue and CANIFARMA. Courtesy Fundacion IDEA.

Life-Sciences Innovation Strengths in Mexico

- A cost-competitive environment for life-sciences innovation.


Competitive costs (% of savings)	
-35.9%	R&D in biotechnology
-31.5%	Clinical trials
-39.3%	Product testing
-14.4%	Pharmaceutical manufacturing

- Increasingly skilled human capital base for biomedical research.
- Diverse ecology (and society) a platform for biomedical innovation.

Source: The Geneva Network, ProMexico, ITIF

Life-Sciences Innovation Opportunities for Mexico

- Recognize that biopharmaceutical value creation comes from R&D and clinical trials, not from the manufacturing.
- Enhance R&D collaboration between biopharmaceutical industry, research institutions, and universities.
- Appropriately value and speed patient access to innovative medicines.
- Continue to improve the intellectual property environment.
- Set a goal of becoming a “G20” life-sciences innovator.



Muchas Gracias!

Stephen Ezell | sezell@itif.org | 202.465.2984